In our small cohort study, pilot data suggest that IL-11 remains a potential and robust blood-based biomarker that is elevated in NSCLC patients, more so than IL-6, IL-8, IL-17A, and IL-33, which have variable detectability across sample sources. Here, IL33 is linked to non-small cell lung carcinoma.